{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-028106","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.363786+00:00","generated_at":"2026-06-01T07:19:46.221354+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gyre subsidiary receives China NMPA IND approval for F230 in pulmonary arterial hypertension","bullets":["IND approved by CDE of China's NMPA for F230 tablets, a selective endothelin receptor antagonist for PAH.","F230 originally licensed from Eisai through Gyre's indirect stockholder GNI Group Ltd.","Preclinical data showed statistically significant reductions in mean pulmonary artery pressure and right ventricular systolic pressure.","CEO Han Ying stated commitment to advancing F230 through clinical development for PAH; other indications also being explored."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-028106","json":"https://secwatch.observer/filing/0001140361-24-028106.json","markdown":"https://secwatch.observer/filing/0001140361-24-028106.md","text":"https://secwatch.observer/filing/0001140361-24-028106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124028106/0001140361-24-028106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124028106/ef20030279-8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:19:46.221354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}